BI 1323495 + midazolam

BI 1323495 + midazolam is a **combination of two drugs**: BI 1323495, an orally available, reversible small molecule inhibitor of neutrophil elastase (NE), and midazolam, a short-acting benzodiazepine commonly used for sedation and as a probe drug in drug-drug interaction studies. BI 1323495 is being developed primarily for conditions associated with neutrophilic airway inflammation, especially non-cystic fibrosis bronchiectasis. Midazolam, in this context, is typically used to assess potential effects of BI 1323495 on cytochrome P450 enzymes (not as a therapeutic pairing). BI 1323495 is developed by Boehringer Ingelheim and is under investigation for chronic lung diseases with neutrophilic inflammation, where neutrophil elastase activity leads to airway damage. Midazolam is a well-established sedative/hypnotic that acts through potentiation of GABA-A receptor activity.